INTRODUCTION

Severe head injury refers to severe damage to brain tissue caused by external forces. It is a common traumatic disease in the Department of Critical Care Medicine, with a high mortality and disability rate.\(^1\) Patients with severe head injury mostly have disturbances in consciousness, and their voluntary energy intake disappears.\(^2\) Patients
with severe head injury are often accompanied by stress ulcers and gastrointestinal mucosal hypoperfusion, and they may cause gastrointestinal mucosal barrier dysfunction and limited nutrient absorption, which is extremely detrimental to their nutrition and rehabilitation. In addition, the inflammatory response after injury may lead to the release of great inflammatory factors, leading to further aggravation of brain tissue damage.3 Adequate enteral nutrition support at an early stage has positive significance for preventing hypoproteinemia, reducing lung infection, reducing patient stress response, adjusting metabolic mechanism, and improving prognosis.4 However, consensus on the formulation of enteral nutrients for patients with a severe head injury is unavailable, and the optimal content of nutrients and total nutritional requirements are still unclear. Currently, there is no effective and best method for monitoring.5 It is undoubtedly very meaningful to formulate individualized nutritional formulas and make certain adjustments for different patients.

In this study, we used individualized nutrition formulas for enteral nutrition for patients with severe head injury. From the perspective of inflammation indicators, immune status, and gastrointestinal tolerance, the individualized nutritional formula and conventional enteral nutrition were compared and analyzed to prove that the former has considerable advantages and is worthy of clinical promotion. Now report the specific situation as follows.

**METHODS**

**Ethical Approval:** The study was approved by the Institutional Ethics Committee of Baoding No.1 Central Hospital, and written informed consent was obtained from all participants.

**Inclusion Criteria:**
1. Clinically diagnosed as craniocerebral injury by CT or MRI.6
2. Aged less than 70 years old.
3. Had severe head injury (GCS score of 3-8).7
4. Had clear signs of positive nervous system.
5. Had family members agreed to the research plan and signed the consent form and were able to cooperate with the research work.

**Exclusion Criteria:**
1. Had unstable hemodynamics.
2. Combined with severe gastrointestinal injury or bleeding who were not suitable for enteral nutrition.
3. Combined with severe dysfunction of important organs and could not be improved after active correction.
4. Combined with tumors or autoimmune diseases.
5. Be intolerant to enteral nutrition.
6. Had drugs affecting the research such as hormones and immunosuppressants in the near future.

A completely random design was adopted in this study. And the sample size of this study was obtained by querying the sample size table. A total of 80 patients with severe head injury admitted to Baoding No.1 Central Hospital from March 2017 to March 2020 were randomly divided into two groups according to the random number table method, with 40 patients in each group. The experimental group included 25 males and 15 females, aged 17-65 years old, with an average of 45.5±15.33 years old, and the control group included 23 males and 17 females, aged 23-67 years old, with an average of 46.4±13.96 years old. There was no significant difference in the general data of the two groups of patients, and the groups were comparable (Table-I).

**Enteral Nutrition Therapy:** The general treatment plan for both groups of patients included close monitoring and control of intracranial pressure, sedation of pain, supportive therapy, prevention of infection, stable cerebral perfusion, etc.8 The control group was given enteral nutrition (EN) through nasointestinal tube based on programs described in ASPEN (American Society for Parenteral and Enteral Nutrition),9 as below: First, keep the hemodynamic stable; apply an infusion pump to continuously pump enteral nutrition at an initial rate of 25ml/h; within three days the calorie volume reaches 25-30kcal/(kg.d), protein reaches 1.5-2.0g/(kg.d), and the blood glucose is controlled at 7.8 ~11.1mmol/L; dynamically evaluate the tolerance; evaluate the gastric residual every six hours; in case of <200mL, increase the EN pumping rate; in case of 200ml-500ml, maintain the original pumping rate; in case of the gastric residual ≥500ml or accompanied by severe diarrhea, vomiting or aspiration, then slow down or suspend EN pumping or replace EN preparations. If this is still not tolerated, change to parenteral nutrition and terminate the study on this patient.

The experimental group was given a more refined and individualized nutritional formula based on the EN program. For patients with digestive dysfunction, nutritional formulas rich in amino acids or short peptides were selected, and for patients with normal digestive tract
function, ensure nutrition containing dietary fiber were selected. For diabetics, low-sugar and rich nutrients such as dietary fiber, monounsaturated fatty acids and fructose were selected, and short-chain fatty acids, soluble dietary fiber, and live bifidobacterium preparations were added to the formula to adjust the intestinal flora and improve the function of the gastrointestinal tract. For patients with urinary disorders, insoluble dietary fiber was added. For patients with anemia, iron, folic acid, vitamin B12, vitamin C and a variety of trace elements were added.

**Observation indicators:** 1) Peripheral venous blood was sampled in the basal state in the morning before intervention at admission and 1d, 7d, and 14d after enteral nutrition therapy. Enzyme-linked immunosorbent assay (ELISA) was used to detect the change of inflammatory factors such as tumor necrosis factor (TNF-a), C-reactive protein (CRP), and interleukin 6 (IL-6); 2) Immune status: Peripheral venous blood was sampled in the basal state in the morning before treatment and 14 days after treatment to detect the immunoglobulins IgA, IgM, and IgG, and analyze their changes. Meanwhile, serum intestinal fatty acid binding protein (I-FABP) and D-lactic acid concentration levels were detected to evaluate the intestinal mucosal barrier function; 3) Gastrointestinal tolerance: The incidence of adverse reactions such as abdominal distension, diarrhea, constipation, and gastric retention within seven days after treatment was compared between the two groups.

**Statistical Analysis:** SPSS 20.0 software was used to calculate all the data, and the measurement data was expressed as (X±S). Independent-samples T test was used for analysis between groups, repeated measures analysis of variance was used for data analysis within groups, and χ² test was used for comparison of rates. The significance level α was set to 0.05 and the confidence interval was 95%.

**RESULTS**

Changes of inflammatory factors in both groups before and after treatment are shown in Table-II, indicating that TNF-a, CRP and IL-6 in both groups were significantly increased before treatment and the difference was not significant (p>0.05); after treatment, the indicators above were lower than those before treatment, and the difference was statistically significant (p<0.05). TNF-a and IL-6 in the experimental group and the control group showed no significant difference at day-one after treatment (TNF-a, p=0.52; IL-6, p=0.33); and seven days and 14d after treatment, the results in the experimental group were significantly lower than those in the control group, with the difference significant (p=0.00). CRP in the experimental group was significantly lower than that in the control group at 1d after treatment (p=0.00), and it decreased significantly at 7d and 14d (p=0.00).

The immunoglobulin levels of both groups of patients improved after treatment compared with before treatment (p=0.00), and the experimental group improved more significantly than the control group after treatment, and the difference was statistically significant (IgG, IgA, p=0.01; IgM, p=0.00) (see Table-III).

The intestinal mucosal barrier function indexes of both groups were improved after treatment compared with before treatment (p=0.00), and the experimental group improved more significantly than the control group after treatment, and the difference was statistically significant (I-FABP, p=0.01; D-lactic acid, p=0.00) (Table-IV).

Within seven days of treatment, the incidence of gastrointestinal adverse reactions in the experimental group was 10% and that in the control group was 27.5%. The gastrointestinal tolerance of the experimental group was significantly better than that of the control group, and the difference was statistically significant (p=0.04).

| Table-I: Comparative analysis of general data of experimental group and control group (X±S) n=40. |
|---|---|---|---|---|
|  | Experimental group | Control group | t/χ² | P |
| Age (years) | 45.55±15.33 | 46.45±13.96 | 0.27 | 0.78 |
| Male (case %) | 25(62.5%) | 23(57.5%) | 0.21 | 0.64 |
| BMI (kg/m²) | 26.13±3.07 | 25.47±2.61 | 1.04 | 0.30 |
| GCS score | 6.46±1.21 | 6.75±2.07 | 0.76 | 0.45 |
| APACHE II score | 21.12±2.11 | 20.25±3.12 | 1.46 | 0.15 |

P>0.05.
DISCUSSION

Nutritional treatment of severe head injury was contradictory to a certain extent. On the one hand, the body was in a state of stress after the injury. The release of stress hormones such as catecholamines and glucagon made the body in a state of high metabolism, and energy consumption was abnormally increased. On the other hand, patients with severe head injury were often unable to take food on their own, leading to a lack of nutrients, and the abnormal glucose and lipid metabolism.

Table-II: Comparative analysis of changes in inflammatory factors before and after treatment in both groups (X±S) n=40.

| Group       | Before treatment* | 1d after treatment | 7d after treatment Δ | 14d after treatment Δ | F   | P   |
|-------------|-------------------|--------------------|----------------------|-----------------------|-----|-----|
| TNF-α (ng/L)|                   |                    |                      |                       |     |     |
| Experimental group Δ | 46.32±12.27       | 27.35±11.43        | 6.77±1.04            | 4.02±2.21             | 21.25 | 0.00 |
| Control group Δ     | 45.53±11.57       | 28.54±11.51        | 11.53±4.35           | 7.15±3.04             | 20.29 | 0.00 |
| t             | 0.67              | 0.65               | 4.31                 | 4.08                  |     |     |
| p             | 0.31              | 0.52*              | 0.00                 | 0.00                  |     |     |
| CRP (mg/L)    |                   |                    |                      |                       |     |     |
| Experimental group Δ | 44.72±7.41        | 16.76±5.03         | 6.47±1.51            | 4.31±0.77             | 34.31 | 0.00 |
| Control group Δ     | 44.53±7.06        | 23.05±6.34         | 10.21±5.33           | 5.22±1.22             | 34.78 | 0.02 |
| t             | 0.65              | 4.92               | 13.42                | 4.25                  |     |     |
| p             | 0.23              | 0.00               | 0.00                 | 0.00                  |     |     |
| IL-6 (ng/L)   |                   |                    |                      |                       |     |     |
| Experimental group Δ | 15.31±5.25        | 10.23±1.72         | 7.21±2.07            | 2.76±0.13             | 15.11 | 0.00 |
| Control group Δ     | 17.33±4.68        | 10.55±1.18         | 9.33±2.53            | 5.25±1.42             | 15.62 | 0.00 |
| t             | 1.82              | 0.97               | 4.10                 | 11.04                 |     |     |
| p             | 0.07              | 0.33*              | 0.00                 | 0.00                  |     |     |

*p>0.05, Δp<0.05.

Table-III: Comparative analysis of immunoglobulin levels before and after treatment of groups (X±S) n=40.

| Observational index | IgG(g/L) | IgA(g/L) | IgM(g/L) |
|---------------------|----------|----------|----------|
|                     | Before treatment * | After treatment Δ | t | p | Before treatment * | After treatment Δ | t | p | Before treatment Δ | After treatment Δ | t | p |
| Experimental group Δ | 7.79±2.13 | 13.25±3.31 | 7.17 | 0.00 | 1.17±0.38 | 2.76±1.43 | 5.09 | 0.00 | 1.43±0.78 | 2.55±0.84 | 6.18 | 0.00 |
| Control group Δ      | 8.73±4.25 | 11.13±4.06 | 2.58 | 0.01 | 1.22±0.46 | 2.15±0.48 | 8.85 | 0.00 | 1.36±0.24 | 2.12±0.23 | 14.46 | 0.00 |
| t                   | 1.25     | 2.56     | 0.53     | 2.56     | 0.54 | 3.12     |
| p                   | 0.21     | 0.01     | 0.60     | 0.01     | 0.60 | 0.00     |

*p>0.05, Δp<0.05.
Individualized Nutritional Formula in Patients with Severe Head Injury

Table-IV: Comparative analysis of intestinal mucosal barrier function indexes before and after treatment of both groups ($\bar{X} \pm S$) n=40.

| Observational index | I-FABP (ug/L) | D- lactic acid(ug/L) |
|---------------------|--------------|---------------------|
|                     | Before treatment * | After treatment Δ | t  | p  | Before treatment * | After treatment Δ | t  | p  |
| Experimental group  | 71.29±9.13    | 19.25±3.36         | 34.16 | 0.00 | 100.27±10.31      | 32.36±3.47         | 39.48 | 0.00 |
| Control group       | 68.73±9.25    | 21.13±3.08         | 30.87 | 0.00 | 103.22±10.46      | 43.75±4.48         | 33.05 | 0.00 |
| χ²                  | 4.02          |                     |       |     | 12.71             |                   |       |     |
| p                   | 0.21          | 0.01                |      |     | 0.20              | 0.00               |      |     |

*p>0.05, Δp<0.05.

Table-V: Comparative analysis of intestinal tolerance after treatment of both groups ($\bar{X} \pm S$) n=40.

| Group          | Abdominal distension | Diarrhea | Constipation | Gastric retention | Total | Incidence |
|----------------|----------------------|----------|--------------|-------------------|-------|-----------|
| Experimental   | 1                    | 1        | 0            | 2                 | 4     | 10%       |
| Control group  | 2                    | 4        | 3            | 2                 | 11    | 27.5%     |
| χ²             |                      |          |              |                   |       | 4.02      |
| p              |                      |          |              |                   |       | 0.04      |

p<0.05.

hypoproteinemia, etc. might cause adverse consequences. Therefore, reasonable nutritional support after injury was of great significance for patients to reduce hypoproteinemia and hypermetabolic state, and to promote recovery.11

In clinical practices, common nutritional support includes parenteral and enteral nutrition. A meta-analysis suggested that early enteral nutrition support after head injury had obvious advantages in improving the prognosis. Our research results showed that feeding through small intestinal and the immune enhancement formula could reduce infectious complications.12 Compared with parenteral nutrition, enteral nutrition was more in line with the physiological state of the normal human body. Enteral nutrition could ensure the blood supply of intestinal wall through the stimulation of enteral nutrients, promote intestinal peristalsis, maintain the permeability and structural and functional integrity of intestinal mucosa, and avoid the movement of intestinal flora to maintain the barrier function of intestinal mucosa. The energy of brain tissue was mainly derived from glucose. Enteral nutrition could increase the concentration of blood sugar and increase the intake of brain tissue, which was of great significance for the repair of damaged brain tissue.13 Meanwhile, nutrients could be absorbed into the liver through the portal vein to promote protein synthesis and regulate high metabolic reactions.14 Reintam et al. believed that15 patients without severe complications such as uncorrectable shock, hypoxemia and acidosis, uncorrectable bleeding, intestinal ischemia or intestinal obstruction, should be given enteral nutrition.

The current enteral nutrition methods mainly included continuous enteral nutrition, intermittent enteral nutrition and compound nutrition support. However, Mazaherpur’s research showed that16 none of the three methods could meet the energy needs of patients. While the continuous method had a positive effect on nitrogen balance, high metabolism reduction and total protein maintenance in the body, and was the preferred method for patients with brain injury. There were many types of enteral nutrition, but consensus on enteral nutrition for patients with a severe head injury was still unavailable. The views of medical and nursing staff might be crucial for patients to receive nutritional therapy, but current research on this aspect was also very limited. During the entire treatment process, close observation of the patient by medical staff and adjustment of the nutritional
In this study, individualized nutritional formula was applied to treat patients with a severe head injury. In addition to conventional nutrients in the nutritional formula, the formulas of different patients were also adjusted according to the literature, such as adding dietary fiber, protein content, monounsaturated fatty acids, fructose, etc. At the same time, the beneficial live bacteria preparation and trace elements were added. Better clinical effects have been obtained. Compared with the traditional nutritional formula, both groups had significantly reduced inflammatory factors such as TNF-α, CRP, IL-6 after treatment, and the difference was significant (p=0.00). After treatment, the immunoglobulin level of the experimental group was significantly improved (IgG, IgA, p=0.01; IgM, p=0.00), and the intestinal mucosal barrier function was significantly improved (I-FABP, p=0.01; D-Lactic acid, p=0.00). And the individualized nutritional formula was adjusted according to the patient’s gastrointestinal condition, the incidence of gastrointestinal adverse reactions was lower and the tolerance was better (p=0.04).

Limitations of this study This study still has shortcomings. In this study, there are few cases and short follow-up time. No further examination and analysis are performed after the occurrence of gastrointestinal adverse reactions to clarify the causes of adverse reactions. We are constantly increasing the sample size and follow-up time in order to elaborate on the shortcomings and long-term effects of individualized nutritional formulas, so that more patients can benefit from it.

CONCLUSIONS

Individualized nutritional formula has more significant advantages than conventional nutritional formula for patients with severe head injury, which can reduce inflammatory response, increase the patient’s immune level, improve the intestinal mucosal barrier function, have good gastrointestinal tolerance, and have a low incidence of adverse reactions. It is worthy of clinical application.

Conflicts of interest: None.

Source of funding: None.

REFERENCES

1. Jiang H, Hao G, Zhang R, Pang Q. Determinants affecting the prognosis of decompressive craniectomy for traumatic brain injury. Pak J Med Sci. 2020;36(4):770-775. doi: 10.12669/pjms.36.4.2045

2. Reintam Blaser A, Starkopf J, Alhazzani W, Berger MM, Casaer MP, Deane AM, et al. Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines. Intensive Care Med. 2017;43(3):380-398. doi:10.1007/s00134-016-4665-0
3. Vieira LV, Pedrosa LAC, Souza VS, Paula CA, Rocha R. Incidence of diarrhea and associated risk factors in patients with traumatic brain injury and enteral nutrition. Metab Brain Dis. 2018;33(3):1755-1760. doi: 10.1007/s11011-018-0487-2

4. Azim A, Haider AA, Rhee P, Verma K, Windell E, Jokar TO, et al. Early feeds not force feeds: Enteral nutrition in traumatic brain injury. J Trauma Acute Care Surg. 2016;81(3):520-524. doi: 10.1097/TA.0000000000001089

5. Badjatia N, Vespa P. Participants of the International Multidisciplinary Consensus Conference on Multimodality Monitoring. Monitoring nutrition and glucose in acute brain injury. Neurocrit Care. 2014;21(Suppl 2):S159-S167. doi: 10.1007/s12028-014-0036-2

6. Rincon S, Gupta R, Phak T. Imaging of head trauma. Handb Clin Neurol. 2016;135:447-477. doi: 10.1016/978-0-444-53485-9.00022-2

7. Jain S, Iverson LM. Glasgow Coma Scale. Glasgow Coma Scale. StatPearls Publishing. 2020.

8. Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2017;80(1):6-15. doi: 10.1227/NEU.0000000000001432

9. Druyan ME, Compher C, Boulatta JI, Braunschweig CL, George DE, Simpser E, et al. Clinical Guidelines For the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients: applying the GRADE system to development of a S.P.E.N. clinical guidelines. JPEN J Parenter Enteral Nutr. 2012;36(7):77-80. doi: 10.1171/0146807111420157

10. Bernini A, Masoodi M, Solari D, Miroz JP, Carteron L, Christinat N, et al. Modulation of cerebral ketone metabolism following traumatic brain injury in humans. J Cereb Blood Flow Metab. 2020;40(1):177-186. doi: 10.1038/s41601-019-0413-7

11. Balakrishnan B, Sailor M, Solari D, Miroz JP, Carteron L, Christinat N, et al. Modulation of cerebral ketone metabolism following traumatic brain injury in humans. J Cereb Blood Flow Metab. 2020;40(1):177-186. doi: 10.1038/s41601-019-0413-7

12. Wang X, Dong Y, Han X, Qi XQ, Huang CG, Hou LJ. Nutritional support for patients sustaining traumatic brain injury: a systematic review and meta-analysis of prospective studies. PLoS One. 2013;8(3):e58838. doi: 10.1371/journal.pone.0058838

13. Koller M, Schiefbeck AJ, Beer R, Gaasch M, Rhomberg P, Stower J, et al. Enteral nutrition increases interstitial brain glucose levels in poor-grade subarachnoid hemorrhage patients. J Cereb Blood Flow Metab. 2018;38(3):518-527. doi: 10.1177/1052786517700434

14. Fan M, Wang Q, Fang W, Jiang Y, Li L, Sun P, et al. Early Enteral Combined with Parenteral Nutrition Treatment for Severe Traumatic Brain Injury: Effects on Immune Function, Nutritional Status and Outcomes. Chin Med Sci J. 2016;31(4):213-220. doi: 10.1016/s1001-9294(17)30003-2

15. Reintam Blaser A, Starkopf J, Alhazzani W, Berger MM, Caspers MP, Deane AM, et al. Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines. Intensive Care Med. 2017;43(3):380-398. doi: 10.1007/s00134-016-4665-0

16. Mazaherpur S, Khately A, Abadi A, Pasdar Y, Najafi F. The Effect of Continuous Enteral Nutrition on Nutrition Indices, Compared to the Intermittent and Combination Enteral Nutrition in Traumatic Brain Injury Patients. J Clin Diagn Res. 2016;10(10):JC01-JC05. doi: 10.7860/JCDR/2016/19271.865

17. Chapple LA, Chapman M, Shalit N, Udy A, Deane A, Williams L. Barriers to Nutrition Intervention for Patients With a Traumatic Brain Injury: Views and Attitudes of Medical and Nursing Practitioners in the Acute Care Setting. JPEN J Parenter Enteral Nutr. 2018;42(2):318-326. doi: 10.1177/1052786516685798

18. Huijben JA, Volovici V, Cnossen MC, Haitsma IK, Stocchetti N, Maas AIR, et al. Variation in general supportive and preventitive intensive care management of traumatic brain injury: a survey in 66 neurotrauma centers participating in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. Crit Care. 2018;22(1):90. doi: 10.1186/s13054-018-2000-6

19. Curtis L, Epstein P. Nutritional treatment for acute and chronic traumatic brain injury patients. J Neurosurg Sci. 2014;58(3):151-160.

20. Rai VRH, Phang LF, Sia SF, Amir A, Veerakumaran JS, Kassim MKA, et al. Effects of immunonutrition on biomarkers in traumatic brain injury patients in Malaysia: a prospective randomized controlled trial. BMC Anesthesiol. 2017;17(1):81. doi: 10.1186/s12871-017-0369-4

21. Painter TJ, Rickerds J, Alban RF. Immune enhancing nutrition in traumatic brain injury - A preliminary study. Int J Surg. 2015;21:70-74. doi: 10.1016/j.ijsu.2015.07.008

22. Lorenz KJ, Schallert R, Daniel V. Immunonutrition - the influence of early postoperative glutamine supplementation in enteral/parenteral nutrition on immune response, wound healing and length of hospital stay in multiple trauma patients and patients after extensive surgery. GMS Interci Anim Nutr. 2015;2014:5:Doc15. doi: 10.3205/ipsr000074

23. Wan G, Wang L, Zhang G, Zhang J, Lu Y, Li J, et al. Effects of probiotics combined with early enteral nutrition on endothelin-1 and C-reactive protein levels and prognosis in patients with severe traumatic brain injury. J Int Med Res. 2020;48(3):300060519888112. doi: 10.1177/0300060519888112

24. Horn SD, Kinikini M, Moore LW, Hammond FM, Brandstatter ME, Smout RJ, et al. Enteral Nutrition for Patients With Traumatic Brain Injury in the Rehabilitation Setting: Associations With Patient Preinjury and Injury Characteristics and Outcomes. Arch Phys Med Rehabil. 2015;96(8 Suppl):S245-S255. doi: 10.1016/j.apmr.2014.06.024

Authors’ Contributions:

CZ & YZ: Designed this study and prepared this manuscript, and are responsible for the accuracy and completeness of the manuscript.

WL: Collected and analyzed clinical data.

QL: Significantly revised this manuscript.

Authors:

1. Chunying Zhu, Department of Neuroscience Critical Care Unit,

2. Yingfu Zhang, Endoscopic Diagnosis and Treatment Center,

3. Wei Li, Department of Neuroscience Critical Care Unit,

4. Qianqian Li, Department of Neuroscience Critical Care Unit,

5. Chunying Zhu and Yingfu Zhang contributed this manuscript equally.

Note: Chunying Zhu and Yingfu Zhang contributed this manuscript equally.